Current approaches to novel therapeutics in pancreatic cancer

Corina E. Akerele, Irina Rybalova, Howard L. Kaufman, Sridhar Mani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.

Original languageEnglish (US)
Pages (from-to)113-129
Number of pages17
JournalInvestigational New Drugs
Volume21
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Pancreatic Neoplasms
gemcitabine
Therapeutics
Standard of Care
Survival
Neoplasms

Keywords

  • New therapeutic modalities
  • Pancreatic cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Current approaches to novel therapeutics in pancreatic cancer. / Akerele, Corina E.; Rybalova, Irina; Kaufman, Howard L.; Mani, Sridhar.

In: Investigational New Drugs, Vol. 21, No. 1, 02.2003, p. 113-129.

Research output: Contribution to journalArticle

Akerele, Corina E. ; Rybalova, Irina ; Kaufman, Howard L. ; Mani, Sridhar. / Current approaches to novel therapeutics in pancreatic cancer. In: Investigational New Drugs. 2003 ; Vol. 21, No. 1. pp. 113-129.
@article{e09cc82661e44a04b1701ce603c6d122,
title = "Current approaches to novel therapeutics in pancreatic cancer",
abstract = "Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.",
keywords = "New therapeutic modalities, Pancreatic cancer",
author = "Akerele, {Corina E.} and Irina Rybalova and Kaufman, {Howard L.} and Sridhar Mani",
year = "2003",
month = "2",
doi = "10.1023/A:1022936914328",
language = "English (US)",
volume = "21",
pages = "113--129",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Current approaches to novel therapeutics in pancreatic cancer

AU - Akerele, Corina E.

AU - Rybalova, Irina

AU - Kaufman, Howard L.

AU - Mani, Sridhar

PY - 2003/2

Y1 - 2003/2

N2 - Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.

AB - Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.

KW - New therapeutic modalities

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0037677399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037677399&partnerID=8YFLogxK

U2 - 10.1023/A:1022936914328

DO - 10.1023/A:1022936914328

M3 - Article

VL - 21

SP - 113

EP - 129

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -